NCT06141070: ANDROMEDA

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

Recruiting now Phase 3 Last updated 14 April 2026

What this trial tests

Phase 3 trial testing Standard systemic therapy + radiotherapy in Non Small Cell Lung Cancer in 240 participants. Currently enrolling.

Timeline

1 December 2023

Primary endpoint
1 December 2028

1 December 2028

Quick facts

Lead sponsor	Vastra Gotaland Region
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	240
Start date	1 December 2023
Primary completion	1 December 2028
Estimated completion	1 December 2028
Sites	6 locations across Sweden

Drugs / interventions tested

• Standard systemic therapy + radiotherapy
• Standard systemic therapy — full drug profile →

Conditions studied

• Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 2:1 randomized multicentre open label phase III study of radiation combined with standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5 metastases) NSCLC. Stratification factors: performance status, gender and systemic strategy. The systemic treatment consists of chemotherapy/chemoimmunotherapy or immunotherapy and is given according to local practice. During the first 3 months of systemic treatment, aiming to start around the 2nd cycle is radiotherapy delivered to all known lesions. Preferably with SBRT /SRT/SRS but conventional radiotherapy may also be used. After the first three cycles of systemic treatment, the patients are assessed, and after four cycles, they are continuing maintenance therapy if indicated. The patients are followed with radiology every three months.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Oligometastatic NSCLC: Current Perspectives and Future Challenges.
   Torresan S, Costa J, Zanchetta C, De Marchi L, et al · · 2025 · cited 6× · PMID 39996875 · DOI 10.3390/curroncol32020075
2. Transforming the Management of Oligometastatic Non-Small Cell Lung Cancer in the Era of Immunotherapy and Targeted Therapy.
   Kawaguchi Y, Takahashi S, Shimada Y, Kudo Y, et al · · 2025 · PMID 41008825 · DOI 10.3390/cancers17182982
3. Insights on Oligometastatic Non-Small-Cell Lung Cancer.
   Valdivia A, Mascaro-Baselga P, Salva-de Torres C, Geng-Cahuayme A, et al · · 2025 · PMID 40805152 · DOI 10.3390/cancers17152451